Friday Apr 9, 2021
9:00 AM - 11:00 AM EDT
April 9
9 - 11 a.m.
Virtual
A webcast of the event can be accessed on the Events & Presentations page of www.g1therapeutics.com. The webcast will be archived on the same page for 90 days following the event.
G1 Therapeutics will review its U.S. launch strategy for the first-in-class myeloprotection therapy, COSELA, in extensive-stage small cell lung cancer. COSELA is the only FDA-approved therapy that helps proactively deliver multilineage myeloprotection benefit to patients with extensive-stage small cell lung cancer being treated with chemotherapy. The program will also feature insights about the urgent need to proactively treat patients for myelosuppression from the following leading clinicians:
Printed courtesy of www.nclifesci.org/ – Contact the NC Life Sciences Organization for more information.
4505 Emperor Blvd, Ste 105, Durham, NC 27703 – (919) 281-8960 – Admin@NCLifeSci.org